Your browser doesn't support javascript.
Show: 20 | 50 | 100
Results 1 - 10 de 10
Filter
1.
Immunity ; 54(10): 2169-2171, 2021 10 12.
Article in English | MEDLINE | ID: covidwho-1461102

ABSTRACT

For new principal investigators, the first years are key to getting a laboratory off the ground and running. COVID-19 has changed the world, bringing on unforeseen difficulties and challenges at every level. We asked these investigators to share their experiences in navigating the unique environment since the start of the pandemic-what has changed in their vision for their laboratory, how they have adapted, and what advice they can share with others in a similar situation.


Subject(s)
COVID-19/epidemiology , Laboratories , Adaptation, Psychological , Biomedical Research/trends , COVID-19/psychology , Communication , Humans , Laboratories/trends , Laboratory Personnel/psychology , Laboratory Personnel/trends , SARS-CoV-2
2.
Cytometry A ; 99(1): 60-67, 2021 01.
Article in English | MEDLINE | ID: covidwho-1384157

ABSTRACT

Data management is essential in a flow cytometry (FCM) shared resource laboratory (SRL) for the integrity of collected data and its long-term preservation, as described in the Cytometry publication from 2016, ISAC Flow Cytometry Shared Resource Laboratory (SRL) Best Practices (Barsky et al.: Cytometry Part A 89A(2016): 1017-1030). The SARS-CoV-2 pandemic introduced an array of challenges in the operation of SRLs. The subsequent laboratory shutdowns and access restrictions brought to the forefront well-established practices that withstood the impact of a sudden change in operations and illuminated areas that need improvement. The most significant challenges from a data management perspective were data access for remote analysis and workstation management. Notably, lessons learned from this challenge emphasize the importance of safeguarding collected data from loss in various emergencies such as fire or natural disasters where the physical hardware storing data could be directly affected. Here, we describe two data management systems that have been successful during the current emergency created by the pandemic, specifically remote access and automated data transfer. We will discuss other situations that could arise and lead to data loss or challenges in interpreting data. © 2020 International Society for Advancement of Cytometry.


Subject(s)
COVID-19/epidemiology , Data Management/trends , Flow Cytometry/trends , Laboratories/trends , Teleworking/trends , COVID-19/prevention & control , Data Management/standards , Flow Cytometry/standards , Humans , Laboratories/standards , Teleworking/standards
3.
Cytometry A ; 99(1): 42-50, 2021 01.
Article in English | MEDLINE | ID: covidwho-916820

ABSTRACT

The impact of the COVID-19 pandemic on training and Shared Resource Laboratory (SRL) operations such as staffing, facility access, and social distancing, has affected facilities around the globe to different degrees based on restrictions set by various geographical and institutional settings. With these restrictions come unique challenges regarding user and staff training and education, for both theory and practice. Most notably, limitations in facility access, occupancy, staffing availability, network restrictions and trainee engagement call for innovative solutions for training when traditional in-person options are not feasible. Through the use of remote access tools and prerecorded educational and training materials, SRLs are able to overcome these obstacles. Here, we focus on readily available technologies and general guidelines that SRLs in different environments can use for remote cytometry training and education, while highlighting key obstacles that still remain. Although SRLs may face initial struggles in transitioning trainings to a virtual format, remote technologies provide unique opportunities to advance current training programs. © 2020 International Society for Advancement of Cytometry.


Subject(s)
COVID-19/prevention & control , Laboratories/trends , Personnel Staffing and Scheduling/trends , Physical Distancing , Teaching/trends , Teleworking/trends , COVID-19/epidemiology , Humans , Pandemics/prevention & control , Workflow
4.
Cytometry A ; 99(1): 68-80, 2021 01.
Article in English | MEDLINE | ID: covidwho-1086342

ABSTRACT

Biosafety has always been an important aspect of daily work in any research institution, particularly for cytometry Shared Resources Laboratories (SRLs). SRLs are common-use spaces that facilitate the sharing of knowledge, expertise, and ideas. This sharing inescapably involves contact and interaction of all those within this working environment on a daily basis. The current pandemic caused by SARS-CoV-2 has prompted the re-evaluation of many policies governing the operations of SRLs. Here we identify and review the unique challenges SRLs face in maintaining biosafety standards, highlighting the potential risks associated with not only cytometry instrumentation and samples, but also the people working with them. We propose possible solutions to safety issues raised by the COVID-19 pandemic and provide tools for facilities to adapt to evolving guidelines and future challenges.


Subject(s)
COVID-19/epidemiology , Containment of Biohazards/trends , Laboratories/trends , COVID-19/prevention & control , COVID-19/transmission , Containment of Biohazards/standards , Flow Cytometry , Humans , Laboratories/standards , Risk Assessment/standards , Risk Assessment/trends
5.
Cytometry A ; 99(1): 51-59, 2021 01.
Article in English | MEDLINE | ID: covidwho-1086341

ABSTRACT

The COVID-19 pandemic has dramatically affected shared resource lab (SRL) staff in-person availability at institutions globally. This article discusses the challenges of ensuring reliable instrument performance and quality data output while facility staff and external service provider on-site presence is severely limited. Solutions revolve around the adoption of remote monitoring and troubleshooting platforms, provision of self-service troubleshooting resources specific to facility instruments and workflows, development of an assistance contact policy, and ensuring efficiency of limited in-person staff time. These solutions employ software and hardware tools that are already in use or readily available in the SRL community, such as remote instrument access tools, video hosting and conferencing platforms, and ISAC shared resources. © 2020 International Society for Advancement of Cytometry.


Subject(s)
COVID-19/epidemiology , Flow Cytometry/instrumentation , Flow Cytometry/standards , Laboratories/standards , Quality Control , Teleworking/standards , COVID-19/prevention & control , Flow Cytometry/trends , Humans , Laboratories/trends , Teleworking/trends , Webcasts as Topic/standards , Webcasts as Topic/trends , Workflow
6.
Cytometry A ; 99(1): 90-99, 2021 01.
Article in English | MEDLINE | ID: covidwho-1086336

ABSTRACT

In March 2020, with lockdown due to the coronavirus pandemic underway, the Francis Crick Institute (the Crick) regeared its research laboratories into clinical testing facilities. Two pipelines were established, one for polymerase chain reaction and the other for Serology. This article discusses the Cricks Flow Cytometry Science Technology Platform (Flow STP) role in setting up the Serology pipeline. Pipeline here referring to the overarching processes in place to facilitate the receipt of human sera through to a SARs-CoV-2 enzyme-linked immunosorbent assay result. We examine the challenges that had to be overcome by a research laboratory to incorporate clinical diagnostics and the processes by which this was achieved. It describes the governance required to run the service, the design of the standard operating procedures (SOPs) and pipeline, the setting up of the assay, the validation required to show the robustness of the pipeline and reporting the results of the assay. Finally, as the lockdown started to ease in June 2020, it examines how this new service affects the daily running of the Flow STP. © 2020 The Authors. Cytometry Part A published by Wiley Periodicals LLC on behalf of International Society for Advancement of Cytometry.


Subject(s)
Adaptation, Psychological , COVID-19/diagnosis , Flow Cytometry/standards , Laboratories/standards , SARS-CoV-2/isolation & purification , COVID-19/blood , COVID-19/epidemiology , Enzyme-Linked Immunosorbent Assay/standards , Enzyme-Linked Immunosorbent Assay/trends , Flow Cytometry/trends , Humans , Laboratories/trends , Reproducibility of Results
7.
J Appl Lab Med ; 6(1): 264-273, 2021 01 12.
Article in English | MEDLINE | ID: covidwho-947659

ABSTRACT

BACKGROUND: Rates of sexually transmitted infections (STI) have risen steadily in recent years, and racial and ethnic minorities have borne the disproportionate burden of STI increases in the United States. Historical inequities and social determinants of health are significant contributors to observed disparities and affect access to diagnostic testing for STI. CONTENT: Public health systems rely heavily on laboratory medicine professionals for diagnosis and reporting of STI. Therefore, it is imperative that clinicians and laboratory professionals be familiar with issues underlying disparities in STI incidence and barriers to reliable diagnostic testing. In this mini-review, we will summarize contributors to racial/ethnic disparity in STI, highlight current epidemiologic trends for gonorrhea, chlamydia, and syphilis, discuss policy issues that affect laboratory and public health funding, and identify specific analytic challenges for diagnostic laboratories. SUMMARY: Racial and ethnic disparities in STI in the US are striking and are due to complex interactions of myriad social determinants of health. Budgetary cuts for laboratory and public health services and competition for resources during the COVID-19 pandemic are major challenges. Laboratory professionals must be aware of these underlying issues and work to maximize efforts to ensure equitable access to diagnostic STI testing for all persons, particularly those most disproportionately burdened by STI.


Subject(s)
Health Services Accessibility/statistics & numerical data , Health Status Disparities , Healthcare Disparities/statistics & numerical data , Laboratories/statistics & numerical data , Sexually Transmitted Diseases/diagnosis , COVID-19/economics , COVID-19/epidemiology , COVID-19/prevention & control , COVID-19 Testing/economics , COVID-19 Testing/statistics & numerical data , Cost of Illness , Ethnicity/statistics & numerical data , Health Care Rationing/trends , Health Services Accessibility/economics , Healthcare Disparities/economics , Humans , Incidence , Laboratories/economics , Laboratories/trends , Minority Groups/statistics & numerical data , Pandemics/economics , Pandemics/prevention & control , Racial Groups/statistics & numerical data , Sexually Transmitted Diseases/epidemiology , Social Determinants of Health/economics , Social Determinants of Health/statistics & numerical data , United States/epidemiology
8.
Clin Chem Lab Med ; 58(7): 1037-1052, 2020 06 25.
Article in English | MEDLINE | ID: covidwho-937253

ABSTRACT

The global coronavirus disease 2019 (COVID-19) has presented major challenges for clinical laboratories, from initial diagnosis to patient monitoring and treatment. Initial response to this pandemic involved the development, production, and distribution of diagnostic molecular assays at an unprecedented rate, leading to minimal validation requirements and concerns regarding their diagnostic accuracy in clinical settings. In addition to molecular testing, serological assays to detect antibodies against severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) are now becoming available from numerous diagnostic manufacturers. In both cases, the lack of peer-reviewed data and regulatory oversight, combined with general misconceptions regarding their appropriate use, have highlighted the importance of laboratory professionals in robustly validating and evaluating these assays for appropriate clinical use. The International Federation of Clinical Chemistry and Laboratory Medicine (IFCC) Task Force on COVID-19 has been established to synthesize up-to-date information on the epidemiology, pathogenesis, and laboratory diagnosis and monitoring of COVID-19, as well as to develop practical recommendations on the use of molecular, serological, and biochemical tests in disease diagnosis and management. This review summarizes the latest evidence and status of molecular, serological, and biochemical testing in COVID-19 and highlights some key considerations for clinical laboratories operating to support the global fight against this ongoing pandemic. Confidently this consolidated information provides a useful resource to laboratories and a reminder of the laboratory's critical role as the world battles this unprecedented crisis.


Subject(s)
Clinical Laboratory Techniques/methods , Coronavirus Infections/diagnosis , Pneumonia, Viral/diagnosis , Betacoronavirus/pathogenicity , Biomarkers , COVID-19 , Clinical Laboratory Services/trends , Coronavirus/pathogenicity , Humans , Laboratories/trends , Pandemics , SARS-CoV-2 , Sensitivity and Specificity
SELECTION OF CITATIONS
SEARCH DETAIL